29 She received liraglutide 0.3 mg SC once daily and metformin 0.5 g 4 times daily
Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
The primary outcome was the impact of GLP-1 agonists on weight loss, including BMI, weight, and WC
As this was a retrospective study, detailed information regarding potential initial dose adjustments or titration strategies was not consistently available in the medical records
Below is a table to compare the side effect profiles: Personal experience goes a long way in how individuals deal with these side effects
The aim is to prevent an athlete from using a substance that may enhance their performance during a game or give them a competitive edge